Next-generation Immunotherapies for Cancer

Our laboratory focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapy with the goal of rationally design innovative next-generation immunotherapies for relapsing/refractory leukemia and lymphoma. 

 

                                                                                                                  

                                                                                         CCI Faculty           Perelman School of Medicine Faculty Page

Kim's time at Penn and with the Ruella Lab is coming to an end! Next stop: Oxford University! 

Members of the Ruella Lab photographed together
From Left to Right: Ki Hyun Kim, PhD, Yong Gu Lee, PhD, Inkook "Ryan" Chun, Kim Amelsberg, Puneeth Guruprasad, Ray Pajarillo, Marco Ruella, MD, Guido Ghilardi, MD, Ruchi Patel

 

 

Talks & Lectures

  • CRISPR-CAS9 KNOCK OUT OF CD5 ENHANCES THE ANTI-TUMOR ACTIVITY OF CHIMERIC ANTIGEN RECEPTOR T CELLS Monday, December 7, 2020 Monday, December 7, 2020 7:00 am - 8:30 am EST

    As part of ASH 62nd's Oral and Poster Abstracts Session title: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Optimizing CAR T cells for Improved Outcomes scheduled for Monday, December 7, 2020: 7:00 AM - 8:30 AM, Virtual Meeting, Channel 21

More Events